Email this article Clinical case of an acquired hemophilia
- Authors: Barlamov P.N.1, Vasilyeva E.R.2, Golubeva M.E.2, Zhelobov V.G.1, Shutylev A.A.3, Kravtsova T.Y.1
-
Affiliations:
- Perm State Medical University named after E.A. Wagner of the Ministry of Healthcare of the Russian Federation
- Medical Unit № 1
- Perm Regional Clinical Hospital
- Issue: Vol 13, No 3-4 (2019)
- Pages: 74-77
- Section: CASE REPORT
- Published: 30.01.2020
- URL: https://klinitsist.abvpress.ru/Klin/article/view/411
- DOI: https://doi.org/10.17650/1818-8338-2019-13-3-4-74-77
- ID: 411
Cite item
Full Text
Abstract
The aim of the work is to describe the clinical case of formation, diagnosis and treatment of the acquired form of blood clotting factor VIII deficiency – of acquired hemophilia A.
Material and methods. Patient R., 71 years, from April 2018, was found an acute hemorrhagic syndrome in the hematomic type of large hematomas manifested submandibular region, neck, chest, right breast, pubic and inguinal regions on the right, the anterior-medial surface of the left femur, anterior surface of left tibia. Standard laboratory tests, computed tomography of soft tissues of the neck, lungs, abdomen; coagulogram; blood clotting factors; inhibitor of factor VIII were evaluated in dynamics during the patient’s stay in the hospital; platelet aggregation function.
Results. Typical gematomny type of bleeding, prolongation of coagulation indicators, the presence of the inhibitor factor VIII (7,0 BAA), the decrease in factor VIII (2 %) allowed diagnosis of acquired hemophilia A. Anti-inhibitory coagulant complex, fresh frozen plasma was successfully used for treatment. The patient is under observation in the regional Hematology center. The hematomas were not renewed.
Conclusion. Our clinical observation demonstrates the features of the course, the algorithm of diagnosis and management of patients with of acquired hemophilia A.
About the authors
P. N. Barlamov
Perm State Medical University named after E.A. Wagner of the Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: pavel-barlamov@yandex.ru
ORCID iD: 0000-0002-8704-692X
26 Petropavlovskaya St., Perm 614990 Russian Federation
E. R. Vasilyeva
Medical Unit № 1
ORCID iD: 0000-0002-0267-9729
68 Gagarina Bul’var, Perm 614077 Russian Federation
M. E. Golubeva
Medical Unit № 1
ORCID iD: 0000-0002-7028-1907
68 Gagarina Bul’var, Perm 614077 Russian Federation
V. G. Zhelobov
Perm State Medical University named after E.A. Wagner of the Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-0780-3116
26 Petropavlovskaya St., Perm 614990 Russian Federation
A. A. Shutylev
Perm Regional Clinical Hospital
ORCID iD: 0000-0003-2859-4229
85 Pushkina St., Perm 614990 Russian Federation
T. Yu. Kravtsova
Perm State Medical University named after E.A. Wagner of the Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-3880-8489
26 Petropavlovskaya St., Perm 614990 Russian Federation
References
- Ershov V.I., Gadaev I.Yu., Budanova D.A. et al. Idiopathic acquired hemophilia with a new missense mutation of factor VIII gene (His2026Arg): literature review and clinical observation. Terapevticheskiy arkhiv = Therapeutic archive 2018;90(7):118–22. (In Russ.).
- Kruse-Jarres R., Kempton C.L., Baudo F. et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol 2017;92(7):695–705. doi: 10.1002/ajh.24777.
- Kessler C.M., Ma A.D., Al-Mondhiry H.A. et al. Assessment of acquired hemophilia patient demographics in the United States: the hemostasis and thrombosis research society registry. Blood Coagul Fibrinolysis 2016;27(7):761–9. doi: 10.1097/MBC.0000000000000582.
- Ewenstein B.M., Putnam K.G., Bohn R.L. Nonhemophilic inhibitors of coagulation. In: C.S. Kitchens, B.M. Alving, C.M. Kessler. Ed. Consultative hemostasis and thrombosis. Philadelphia, PA: W.B. Saunders, 2002. Рp.: 5–90.
- Prasolov N.V., Bulanov A.Yu., Shulutko E.M., Orel E.B. Acquired hemophilia in elderly patients. Klinicheskaya gerontologiya = Clinical gerontology 2015;21(9–10):16–24. (In Russ.).
- Dentale N., Fulgaro C., Guerra L. et al. Acquisition of factor VIII inhibitor after acute hepatitis C virus infection. Blood 1997;90(8):3233–4.
- Chernov V.M. Inhibitory hemophilia: screening, diagnosis, treatment. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Questions of hematology/oncology and immunopathology in pediatrics 2009;8(3):33–9. (In Russ.).
- Wootla B., Mahendra A., Dimitrov J. Factor VIII – hydrolyzing IgG in acquired and congenital hemophilia. FEBS Letters 2009;583(15):2565–72. doi: 10.1016/j.febslet.2009.07.009.
- Baudo F., Collins P., Huth-Kuhne A. et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Hemophilia (EACH2) Registry. Blood 2012;120(1):39–46. doi: 10.1182/blood-2012-02-408930.
- Franchini M. Rituximab in the treatment of adult acquired hemophilia A: systematic review. Crit Rev Oncol Hematol 2007;63(1):47–52. doi: 10.1016/j.critrevonc.2006.11.004.
- Feinstein D.L., Akpa B.S., Ayee M.A. et al. The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures. Ann N Y Acad Sci 2016;1374(1):111–22. doi: 10.1111/nyas.13085.
Supplementary files
